scholarly journals Pre-Clinical Investigation of Liquid Paclitaxel for Local Drug Delivery: A Pilot Study

2020 ◽  
Vol 13 (12) ◽  
pp. 434
Author(s):  
Claire V. Cawthon ◽  
Kathryn Cooper ◽  
Clifton Huett ◽  
Alyssa Lloret ◽  
Estefanny Villar-Matamoros ◽  
...  

The purpose of this pilot study was to investigate the feasibility of a perfusion catheter to deliver liquid paclitaxel into arterial segments. A clinically relevant rabbit ilio-femoral injury model was utilized to determine the impact of liquid paclitaxel delivered locally into the vessel wall using a perfusion catheter at 1 h to 14 days. Treatment by two clinically available forms of liquid paclitaxel, a solvent-based (sb) versus an albumin-bound (nab), along with a control (uncoated balloons), were investigated. Pharmacokinetic results demonstrated an increase in the retention of the sb-paclitaxel versus the nab-paclitaxel at 1 h; however, no other differences were observed at days one, three, and seven. Histological findings at 14 days showed significantly less neointimal area in the sb-paclitaxel treated arteries as compared with the nab-paclitaxel and the uncoated balloon-treated arteries. Additionally, percent area stenosis was significantly less in the sb-paclitaxel group. These results support the concept of local liquid delivery of paclitaxel into the arterial segments.

2012 ◽  
Vol 59 (13) ◽  
pp. E216
Author(s):  
Bruno Scheller ◽  
Bodo Cremers ◽  
Yvonne Clever ◽  
Michael Böhm ◽  
Ulrich Speck

2011 ◽  
Vol 469 (11) ◽  
pp. 3008-3015 ◽  
Author(s):  
Ashley C. Parker ◽  
J. Keaton Smith ◽  
Harry S. Courtney ◽  
Warren O. Haggard

2020 ◽  
Vol 40 ◽  
pp. 38-57
Author(s):  
UC Woelfle ◽  
◽  
T Briggs ◽  
S Bhattacharyya ◽  
H Qu ◽  
...  

2002 ◽  
Vol 3 (3-4) ◽  
pp. 163-168 ◽  
Author(s):  
Julie M. Burgher ◽  
Jennifer M. Barton ◽  
Michael M. Farooq ◽  
Jeff Vasek ◽  
Robert W. Scott ◽  
...  

2007 ◽  
Author(s):  
Danielle V. Shelov ◽  
Sonia Suchday ◽  
Jennifer P. Friedberg
Keyword(s):  

2018 ◽  
Vol 5 (3) ◽  
pp. 175-187 ◽  
Author(s):  
O. V. Gorovtsova ◽  
T. L. Ushakova ◽  
V. G. Polyakov

Retinoblastoma is one of highly curable diseases; today the total 5-year survival rate in patients with retinoblastoma exceeds 95%. The article summarizes the current world experience on treatment of patients with intraocular retinoblastoma. The treating skills of intraocular malignant tumor in children are a balance between the patient’s life and the preservation of an eye and its visual functions. The complex and challenging task is the treatment of common intraocular retinoblastoma groups «C», «D», «E» when the large size or localization of the tumor does not allow performing the local (focal) destruction of the tumor. As a rule, in such cases neoadjuvant chemotherapy (CT) is performed at the first stage in order to reduce the size of the tumor for further focal therapy. However, the analysed data on the effectiveness of neoadjuvant CT in combination with focal or radiotherapy demonstrated the limited possibilities of the proposed therapy. Local drug delivery in cancer therapy became a real breakthrough in the organ-preserving treatment of children with large intraocular retinoblastoma. The most widely used current methods of local drug delivery are intravitreal (IVitC) and selective intra-arterial chemotherapy (SIAC) as monotherapy or in combination with neoadjuvant CT and focal therapy which significantly increased the percentage of preserved eyes without radiotherapy administration or damage to the patient survival. The review discusses the different IVitC and SIAC techniques, chemotherapy schemes, dosages of chemotherapy, immediate and long-term complications of treatment.


Sign in / Sign up

Export Citation Format

Share Document